Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492902 | 0.89 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22516419 | 0.88 | BRD4 (0.79) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22492905 | 0.87 | BRD4 (0.82) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL28465833 | 0.87 | BRD4 (0.77) | BRD4 | |
| SCHEMBL22492900 | 0.87 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22516421 | 0.85 | BRD4 (0.90) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22492922 | 0.85 | BRD4 (0.77) | BRD4 | |
| SCHEMBL29977106 | 0.85 | BRD4 (0.77) | BRD4 | |
| SCHEMBL22492854 | 0.84 | BRD4 (1.00) | BRD4 | |
| SCHEMBL28465834 | 0.84 | BRD4 (0.81) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-10-11 | — | — | US | claimed |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2020-12-10 | — | — | US | claimed |
| EP-3719017-A2 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | Betta Pharmaceuticals Co., Ltd. (CN) | 2020-10-07 | — | — | EP | claimed |
| US-11845762-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20230022091-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230022091-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| EP-3719017-A2 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | Betta Pharmaceuticals Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719017-A2 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | Betta Pharmaceuticals Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BRD4, BRD1, BRD2 | BRD4 1/4885BRD2 3/4885ADORA2B 4634/4885 |
| US-20230022091-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BRD4, BRD1, BRD2 | BRD4 1/4885BRD2 3/4885ADORA2B 4634/4885 |
| US-11845762-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BRD4, BRD1, BRD2 | BRD4 1/4885BRD2 3/4885ADORA2B 4634/4885 |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BRD4, BRD1, BRD2 | BRD4 1/4885BRD2 3/4885ADORA2B 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.